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 Abstract 
 
Following radical orchidectomy for testicular cancer, most patients undergo 
protocolled surveillance to detect tumour recurrences rather than receive adjuvant 
chemotherapy. Current UK national and most international guidelines recommend 
that patients require a chest x-ray (CXR) and serum tumour markers at each follow 
up visit as well as regular CT scans, there is however, variation among cancer 
centres with follow up protocols. Seminomas often do not cause tumour marker 
elevation; therefore CT scans are the main diagnostic tool for detecting relapse. For 
non-seminomatous tumours, serum beta-HCG (HCG) and AFP levels are a very 
sensitive harbinger of relapse, but this only occurs in 50% of patients (1)and 
therefore imaging remains as important. CXRs are meant to aid in the detection of 
lung recurrences and prior to the introduction of modern cross sectional imaging in 
the early 1980s, CXRs would have been the only method of identifying lung 
metastasis. We examined the Thames Valley and Mount Vernon Cancer Centre 
databases to evaluate the role of CXRs in the 21st century for the follow up of men 
with stage 1 testicular cancer between 2003 and 2015 to assess its value in 
diagnosing relapsed germ cell tumours. From a total of 1,447 patients we identified 
159 relapses. All relapses were detected either by rising tumour markers or planned 
follow up CT scans. Not a single relapse was identified on CXR. We conclude that 
with timely and appropriate modern cross-sectional imaging and tumour marker 
assays, the CXR no longer has any value in the routine surveillance of stage 1 
testicular cancer and should be removed from follow up guidelines and clinical 
practice. Omitting routine CXR from follow up schedules will reduce anxiety to 
patients with every visit, the time patients spend at hospitals and result in significant 
cost savings. 
 
  
Introduction 
Testicular cancer is the most common solid organ malignancy in the 15-35 year old 
group and one of the most curable malignancies among all cancers worldwide. Cure 
rates in stage 1 disease are approximately 99% and can exceed 90% in patients with 
metastatic disease(2, 3). The relapse rates for patients with seminoma vary 
depending on known risk factors such as tumour size >4cm and rete testis 
invasion(4) whereas for non-seminomatous or mixed tumours, lymphovascular 
invasion is a risk factor for recurrence(5). Despite such risk factors, approximately 
83% of stage 1 seminomas and 70% of stage 1 non-seminomas will be cured with 
orchidectomy alone(6) and in case of relapse, >99% patients can be routinely cured 
with platinum based chemotherapy such as BEP (Bleomycin, Etoposide, Cisplatin 
/ Carboplatin)(7, 8).  
Although adjuvant chemotherapy has a role in reducing the relapse rates in both 
seminoma and non-seminomatous tumours(9), it is not routinely offered although 
both the SWENOTECA group and the recent BEP 111 data (using 1 cycle of 
adjuvant BEP in high risk non-seminomatous stage 1 patients) will become practice 
changing for a lot of clinicians (10, 11). In addition, given that less than 30% 
patients require systemic chemotherapy, it would result in gross overtreatment of 
over 70% of patients and exposure to the well recognised toxicities chemotherapy 
can cause in the short and long term such as permanent skin changes, pulmonary 
disease, cardiovascular disease, gastro-intestinal, renal and neurological 
disorders(12, 13); Close follow up to detect early relapse is therefore paramount. It 
has been well established that surveillance schedules are both safe and effective in 
identifying those who relapse and require curative chemotherapy. 
 
The majority of relapses (>90%) occur within 2 or 3 years post orchidectomy(1) 
and follow up is therefore more intensive during this period, but late relapses after 
5 years can also occur.  Over 80% of relapses in patients with seminoma and 70% 
of relapses in non-seminomatous patients occur outside the chest and the most 
common site of recurrence are nodal masses in the retroperitoneum making chest 
imaging as part of routine follow up questionable(1, 9).  
 
Follow up guidelines and imaging modalities after orchidectomy vary among 
centres (Table 1). Our follow up practice is based on national and international 
guidance such as the European Association of Urology (EAU)(14) and the National 
Comprehensive Cancer Network (NCCN)(15) using CXRs and CT scans routinely 
as shown in Table 1. Table 2 details the specific active surveillance strategies for 
seminoma and non-seminomatous tumours in both Thames Valley and Mount 
Vernon. The main differences are, that in Thames valley, a CT is performed for 
patients with non-seminomatous tumours at 3 years and for high-risk seminoma 
patients at Mount Vernon follow up is continued annually for 5-10 years.  
The Thames Valley follow up for non-seminomatous tumours includes tumour 
markers (AFP, HCG, LDH) and CXR (except if having CT) at every clinic visit, 
detailed in Table 2. CT scans (Thorax abdomen and pelvis) are performed at 3 
months; 1 year and 3 years post orchidectomy. At Mount Vernon the follow-up for 
this group is identical with the omission of LDH measurements and no CT scan at 
3 years (only baseline, 3 months and 1 year; not including chest). Patients with 
seminoma are seen in clinic at month 1, then 3 monthly for 2 years, then 6 monthly 
to 5 years when those at low risk are discharged. At Mount Vernon, those with 
seminoma and high-risk features continue to be seen annually for a further 4-5 
years. Patients with non-seminomatous germ cell tumours are seen monthly for the 
1st year, then 2-monthly the 2nd year, 4-monthly the 3rd year and 6-monthly 
afterwards until year 5 when they are discharged. 
 
Given the different approaches among centres regarding the utility and frequency 
of different imaging modalities (abdominal ultrasound, CXR, CT, MRI) in the role 
of testicular cancer follow up, we conducted a review of practices in the Thames 
Valley and Mount Vernon Cancer Centre to determine if CXRs in particular have a 
place in testicular cancer follow up. We identified all patients with germ cell relapse 
between 2003 and 2015 from the Thames Valley and Mount Vernon databases who 
relapsed having presented with Stage 1 disease. We identified the number of CXRs 
performed for each patient as part of their surveillance and reviewed the images or 
reports. We assessed the incidence and location of relapse, as well as the methods 
by which these relapses were detected.  
 
  
Methods 
The Thames Valley database was designed using MySQL relational database 
management system in a Trust Server; a web based front-end application with 
secured login and password to maintain patient confidentiality. All new cases are 
discussed at multi-disciplinary team (MDT) meetings where pathology and 
radiology are centrally reviewed and appended to the database by an automated 
process and updated regularly with clinical follow up data. This publication is a 
retrospective assessment of a combination of all Stage I germ cell cases offered 
surveillance at diagnosis and registered at Mount Vernon Cancer Centre (Northwick 
Park, North Middlesex, Watford, Luton & Dunstable, Stevenage, Hillingdon) and 
Thames Valley (Oxfordshire, Milton Keynes, Reading, High Wycombe, Stoke 
Mandeville, Swindon and Slough) between 2003 and 2015. Ethical approval was 
not required for this service evaluation audit, which is registered in the UK’s 
National Clinical Audits directorate (ID number: 4072) via the Oxford University 
Hospitals, NHS Foundation Trust and East and North Hertfordshire NHS Trust (ID 
number: 10215). 
 
 
 
 
 
 
 
 
 
Results 
We identified 1,447 patients with a confirmed diagnosis of testicular cancer (886 
seminomas, 561 non-seminomas) who underwent orchidectomy between 2003 and 
2015. 11 patients with seminoma and 14 patients with non-seminomatous tumours 
were lost to follow up due to transfer of care to other centres. There were 164 
confirmed relapses. Five relapsed patients from Thames Valley were excluded from 
the analysis due to lack of information (no clinical notes or electronic information 
available) leaving a total of 159 patients with relapsed testicular cancer (Table 3).  
 
For patients with seminoma, 89% (n=74) of all relapses occurred within the 
abdomen (Table 4), 4% (n=3) in the mediastinum and 1% (n=1) in the lung.  1 
patient developed a contralateral second primary germ cell tumour.  Relapse was 
identified in 6% (n=5) based on raised tumour markers alone with no measurable 
disease (biochemical relapse). The patients who developed lung metastases did not 
have abnormal CXR findings, despite a contemporaneous CT scan confirming 
relapse. 84% (n=70) of relapsed seminomas were detected on routine CT scans, 
15% (n=12) through raised tumour markers, prompting early CT scan and 1% (n=1) 
on abdominal MRI.  No relapse was detected on CXR  (Table 6).  
 
For patients with non-seminomatous tumours, 85% (n=64) of relapses occurred in 
the retroperitoneum, 4% (n=3) in the mediastinum, 5% (n=4) in the lungs, 1% (n=1) 
in brain/spine and in 5% (n=4) treatment for relapse was based on raised tumour 
markers alone (Table 4). 62% (n=47) of non-seminoma relapsed patients were 
identified initially on CT scan and 38% (n=29) by raised tumour markers (Table 5). 
Of those patients with lung metastases (5%, n=4), only one patient had CXR 
changes, however this patient’s AFP had risen to 4,000, which triggered an early 
CT scan confirming lung metastases; the CXR was unnecessary. Lung metastases 
were not seen on CXRs performed concurrently with routine surveillance CTs in 4 
patients.   
Incidental findings were detected on surveillance CXR in this population: one case 
of tuberculosis, one lobar pneumonia and one small pneumothorax were identified 
in the Mount Vernon population over this period.  The mean time to relapse in the 
lungs post orchidectomy for seminomas was 11.5 months (from 4 to 19 months) 
and for non-seminomas was 6.3 months (from 2 to 13 months). Over half of patient 
with lung metastasis had concomitant retroperitoneal nodal relapse. 
 
  
Discussion 
The frequency and schedule of surveillance CXRs, CTs (or MRIs) used in testicular 
cancer follow up varies between countries and centres. Most centres use a total of 3 
to 5 CT scans over a 5-year period. Some centres, such as Mount Vernon, only 
image (CT) the retroperitoneum / abdomen (excluding chest) to minimise radiation 
exposure where appropriate(5, 6, 14, 15).  
 
CTs have a much better predictive value compared to plain CXR in detecting lung 
metastases(16). Both these imaging modalities involve exposure to ionising 
radiation, which should be minimised due to an increased risk of secondary 
malignancies, particularly in this young patient population expected to live a normal 
life expectancy after successful treatment. The CXR played a pivotal role in the 
diagnosis of chest pathology before the mid 1980’s, prior to the widespread 
availability of CT imaging(17). It is likely that many germ cell surveillance 
protocols only include CXR now, as it was firmly embedded in routine clinical 
practice from this time. Worldwide, guidelines do not always keep up with the speed 
of technological advances. As novel imaging modalities are introduced and shown 
to be safe and more effective, they should be introduced to replace older modalities.  
Studies have been exploring the optimal frequency and mode of cross sectional 
imaging for retroperitoneal relapse.  The TRISST(18) trial is aiming to address the 
frequency of surveillance CTs and MRIs for patients with stage 1 seminoma (results 
awaited). The TE08 study(19) described the non-inferiority of undertaking 2 versus 
5 additional CT scans (after initial staging) for the reassessment of patients with 
stage 1 non-seminomatous germ cell tumours. No prospective study has evaluated 
the ongoing role for CXR.  This is particularly important because it is likely that 
with the improved ability to detect nodal relapse, fewer patients will go on to 
develop visceral metastases (i.e. lung) nowadays, as they are likely to be treated 
earlier. 
 
According to the Thames Valley / Mount Vernon guidelines, a patient with a 
seminoma will require 12 CXRs and those with non-seminoma 22 CXRs during 5 
years of follow up. Similarly in Australia, the reported average number of CXR is 
9 for patients with seminoma and 10 for patients with non-seminoma undergoing 
surveillance(20). The range of CXR’s was 0-30, which is similar to this review.  It 
is difficult to accurately calculate the expense and cost per CXR during the 12-year 
period analysed in this study. It is also debatable whether the cost per CXR should 
include the cost involved in reporting by radiologists. Therefore the cost of a single 
CXR can vary from £26 to £100. Every network/Trust will therefore spend from 
£312 to £1,200 per seminoma patient on CXRs alone and £572 to £2,200 per non-
seminomatous patient. To date, it is estimated that Mount Vernon Cancer Centre 
and the Thames Valley germ cell surveillance practice has cost between £607,880 
to £2,338,000 in CXRs alone for the low (£26) and high (£100) estimates of CXR 
quotes.  
 
Repeated CXRs increase the radiation exposure to these, often young, adults. The 
dose of a typical postero-anterior CXR is 0.014mSv, which corresponds to a lifetime 
risk of detriment from fatal cancer of approximately 1 in 1 million(21-23). This 
compares with the natural lifetime risk of fatal cancer of approximately 1 in 3. It is 
equivalent to the risks from natural background radiation of 3 days. The radiation 
exposure per CXR is very low and should not be significant in isolation, however 
repeated unnecessary exposure should be avoided. If a patient completes all planned 
CXRs on their surveillance program, they will receive 0.168mSv and 0.308mSv as 
a cumulative dose per seminoma and non-seminomatous diagnosis, (36 and 66 days 
of natural background radiation) respectively.  
 
We have described the use of CXR in the routine surveillance of a large cohort 
(1,447) of germ cell cancer patients. Other centres and series have shown similar 
results (Table 6). Cunniffe et al examined their relapse rate in over 6,000 patients 
with stage 1 seminomas and non-seminomas over a 10-year period (2000–
2010)(24).  As part of this analysis it was apparent that no relapse was identified 
from CXR. Kolmannsberger et al investigated 221 relapses out of 2,483 stage 1 
seminoma and non-seminomatous tumours over a 12-year period (1998-2010)(1).  
Two patients (0.08%) had their recurrent germ cell tumour diagnosed from routine 
CXRs. Daugaard et al analysed 382 relapses in their 1,226 patient population (1984-
2007 period) with stage 1 non seminomatous tumours including high risk patients 
with lymphovascular invasion, rete invasion and embryonal carcinoma 
components; once again tumour markers detected early relapse and CTs late relapse 
with CXRs playing no role(25). Cummins et al showed 1 patient had germ cell 
tumour recurrence detected by CXR from 22 relapses in their 164 stage 1 seminoma 
cohort(26). Following a review by Tolan et al., where 527 patients with stage 1 
seminoma were investigated and 73 of 74 relapses were detected by CT abdomen-
pelvis, none on CXR alone, Canadian clinicians (as the SWENOTECA group) 
reviewed their national guidance and have omitted routine CXR from their 
surveillance protocols(26, 27). 
 
With modern CT scanners and reliable tumour markers, we conclude that from our 
review, CXRs no longer have a role in diagnosing germ cell tumour relapse. 89% 
of seminomas metastasise outside the chest and CXR did not detect any of the 
proven lung metastases identified by CT scanning. 85% of non-seminomas relapse 
outside the chest. A single case of lung relapse was detected by CXR after AFP of 
4,000 triggered imaging (CT scanning). In this study, lung relapses (detected by 
CT) were not evident on concurrent CXRs. Additionally, misleading CXRs with 
nipple shadows or other artefacts, can lead to extra unnecessary CT scans (data not 
shown) and anxiety for patients. 
 
As in Canada and the SWENOTECA group, we suggest that other centres both 
nationally and internationally should change their clinical practice and current 
guidelines should be reviewed in line with these findings. We hope these core data 
become an integral and fundamental pillar in forming uniform national germ cell 
surveillance follow up guidelines. Similarly, we also show here that clinical 
examination has limited value in diagnosing germ cell relapse, supporting the 
rationale for patients to undergo a less onerous follow up protocol regime based on 
tumour markers and CT scans alone, as poor patient compliance (data not shown) 
in the follow up schedule can be an issue in this young patient population. 
 
Following surgery, strategies to maintain safe and adequate surveillance with 
measurement of tumour markers and limited cross-sectional imaging are required. 
Some of this population need reminding of the importance of complying with these 
interventions.  Reducing the number of mandatory hospital visits may help in this 
respect.  Revision of national UK surveillance guidelines to exclude routine CXR 
is a first step and perhaps the use of more modern technology such as smart phone 
applications, which are increasingly being used in the medical field, will drive 
further modifications to improve patient compliance with surveillance programmes. 
* Conflict of Interest Statement: Authors disclose no financial, personal or other 
conflict of interest. 
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TABLE 1: International protocols for Surveillance follow up in Stage 1 germ cell 
tumours 
 
 
Group Year of 
follow up 
Clinic/markers CT A+P CXR 
ESMO 
 
1 3m 6m 6m 
2 3m 6m 6m 
3 4m Annually Annually 
4 6m Annually Annually 
5 6m Annually Annually  
6-10 Annually   
SIGN 1 3m 6m 3m 
2 3m 6m 3m 
3 6m Annual 6m 
4 6m Annual 6m 
5 6m - 6m 
6-10 Annually - Annually 
NCCN 1 2m 4-6m Twice 
2 3m 6-12m Annually 
3 4-6m Annually Annually 
4 6m 12-24m Annually* 
5 Annually 12-24m Annually* 
EAU- Seminoma 1 4m 6m 6m 
2 4m 6m 6m 
3 Annually  Annually 
4 Annually   
5 Annually  Annually 
EAU- NSGCT 1 3m 3 &12m 6m 
2 3m Annually 6m 
3 3m Annually 6m 
4 Annually  6m 
5 Annually  6m 
ESMO: European Society Of Medical Oncology; SIGN: 	Scottish Intercollegiate 
Guidelines Network 
*Seminoma- Only if clinically indicated- CT chest in symptomatic patients 
m= months 
EAU- European Association of Urology 
 
 
 
 
 
 
 
 
 	
Table 2: Follow up schedule at MVCC and Thames valley 
 
 
 
 
 
 
 
TABLE 3: Patients demographics  	
Centre Number of evaluable 
relapses (range) 
  
MVCC 100 
Thames Valley 59 
Total 159Ψ  Median	age	at	diagnosis 34	years	(11-86) Median	number	of	CXR**	 12	(0-34)		
Stage at Presentation Seminoma Non-seminomas 
Stage 1 89% (n=83) 81% (n=76) 
TOTAL= 159 n=83 n=76 
Ψ excluded due to insufficient data  
* Thames Valley cohort only 
**MVCC 
 
 
ORGANIZATION Year of 
follow up 
Clinic/markers CT A+P CXR 
Thames Valley- 
Seminoma 
 
1 1m then 3m 3 & 12m* 1m then 3m 
2 3m  3m 
3 4m Annually* 4m 
4 6m  6m 
5 6m  6m 
Thames Valley- 
NSGCT 
 
1 Monthly 3 & 12m* Monthly 
2 2m  2m 
3 4m Annually* 4m 
4 6m  6m 
5 6m  6m 
MVCC 
 
1 3m 6m, 12m 3m 
2 3m 24m,  3m 
3 4m 36m 4m 
4 6m  6m 
5 6m Discharge if 
low risk 
 6m 
6-10 12m  Alt 12m 
*Thames valley had CT Thorax as well as part of Surveillance follow up 
 
 
TABLE 4: Nature of relapse  	
Site of Relapse 	 Seminomas	 Non-Seminomas	
Abdo/Pelvis*	 89%   (n=74)	 85%   (n=64)	
Mediastinum	 4%   (n=3)	 4% (n=3)	
Lungs	 1%   (n=1)	 5%   (n=4)	
Brain/Spine	 0%   (n=0)	 1%   (n=1)	
Biochemical Relapse**	 6% (n=5)	 5% (n=4)	
Total	 100%   (n=83)	 100%   (n=76)			
NOTE: *Abdomen/Pelvis: Includes Iliac, retroperitoneal, retro-precaval, paraaortic 
and liver metastasis. **Biochemical Relapse: Positive tumour markers without 
objective anatomical relapse on imaging. 
 
Table 5: Modality of relapse detection  
 Relapse	Detection Seminomas Non-Seminomas CT	Scan 84%			(n=70) 62%			(n=47) Tumour	Markers 15%			(n=12) 38%	(n=29) CXR 0%			(n=0) 0%			(n=0) MRI 1%	(n=1) 0%	(n=0) Total	 100%			(n=83)	 100%			(n=76)	
 
 
TABLE 6: Published Multicentre Analyses which detail role of CXR  
 
Author, publication year 
(actual years and type 
GCT reviewed) 
Germ Cell Cases on 
Surveillance 
Relapses Diagnosed By 
CXR 
De La Pena et al, 2017  
(2003-2015, seminoma 
and non-seminoma) 
1447 0 
Cunniffe et al, 2012 
(2000-2010, seminoma 
and non-seminoma) 
6000 0 
Kolmansberger et al, 2015 
(1998-2010, seminoma 
and non-seminoma) 
2483 2 
Daugaard et al, 2014 
(1984 – 2007, non-
seminoma) 
1226 0 
Cummins et al, 2009 
(1980 – 2004, seminoma) 
164 1 
Tolan et al, 2010 
(1982 – 2005, seminoma) 
527 0 
Total 11847 (100%) 3 (0.02%) 
	
